UB#INBIORC2611D

Goldman Sachs Raises Earnings Forecast and Target Price for Innovent Biologics

CICC Maintains Overweight Industry Rating for Innovent Biologics, Anticipates Continued Revenue Growth

Innovent Biologics Q1 2026 Revenue Exceeds RMB 3.8 Billion with YoY Growth of Over 50%

BofA Securities Reports: CStone Pharmaceuticals Sees Strong February Drug Sales

Innosyn Biologics to Present Clinical Data on IBI363 and TYVYT at the 2026 ASCO Annual Meeting

Ede Ronald Hao Xi reduced holdings of Innovent Biologics to 1 million shares

Innovative Drug Margetide's Phase II Clinical Trial Results Published in Cell Journal

CICC Report Analyzes Innovent Biologics 2025 Performance and Provides Rating Recommendations

UBS Cuts CSB Biopharma EPS Forecast but Maintains Buy Rating

Citi Raises Rating and Target Price for Innovent Biologics

Goldman Sachs Report: Innovent Biologics Surpassed Revenue Expectations in H2 2022

INNOVENT BIO released FY2025 9 Months Earnings on March 26, 2026 (BJT) with actual revenue of HKD 6.446 B and EPS of HKD 0.5305

INNOVENT BIO released FY2025 Q3 earnings on March 26 (BJT), actual revenue HKD 3.874 B, actual EPS HKD -0.0066

INNOVENT BIO released FY2025 Q4 earnings on March 26 After-Market (BJT), actual revenue HKD 3.941 B, actual EPS HKD -0.0067

INNOVENT BIO released FY2025 Annual Earnings on March 26 After-Market (BJT), Actual Revenue: HKD 14.25 B (Forecast: HKD 14.83 B), Actual EPS: HKD 0.5136 (Forecast: HKD 1.07)

Innovent Biologics Announces Profitable Year, Reversing Previous Losses

Innovent Biologics Clarifies Strategic Cooperation Agreement Not an Acquisition

JPMorgan Increases Stake in Innovent Biologics by 497,823 Shares

INNOVENT BIO to release FY2025 earnings on March 26 After-Market (BJT), forecast revenue HKD 15.22 B, EPS HKD 1.0976

JPMorgan Increases Stake in Innovent Biologics to 5%

SOMERLEY CAP

TIANLI HOLDINGS

CPM GROUP

FUTONG TECH

NICHE-TECH SEMI

SINO ICT

COSMOS MACH

UBOT HOLDING

SAMPLE TECH

PERENNIAL INT'L

01801

CICC analyst maintained a Buy rating on Innovent Biologics yesterday and set a price target of HK$118.30.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Currently, the analyst consensus on Innovent Biologics is a Strong Buy with an average price target of HK$118.15.

Tip Ranks

INNOVENT BIO

CICC

CICC Sticks to Their Buy Rating for Innovent Biologics (IVBXF)

G Sachs has raised the target price for INNOVENT BIOto HKD105.94 following a strong 1Q26 performance, where product revenue exceeded RMB3.8 billion, up over 50% YoY. This surpassed the broker's forecast of RMB3.5 billion, driven by product portfolio expansion. G Sachs also increased EPS forecasts for 2026 to 2028 and maintained a Buy rating. Key data releases in June at the ADA and ASCO conferences are anticipated to attract market attention.

AASTOCKS News

Goldman Sachs

GS Hldg R

G Sachs Raises INNOVENT BIO  TP to HKD105.94; 1Q Product Sales Beat

INNOVENT BIOreported a product revenue exceeding RMB3.8 billion in 1Q26, marking a year-on-year increase of over 50%. This growth is attributed to the inclusion of five tyrosine kinase inhibitors in the National Reimbursement Drug List, leading to rapid volume expansion. Key products driving revenue include Sintilimab, Xinbile, and Xinbimin. The company is also advancing three promising molecules into Phase III clinical trials and continues to invest in early-stage innovations across various therapeutic areas.

INNOVENT BIO  1Q26 Product Revenue Exceeds RMB3.8 billion, Up Over 50% YoY

01888

02338

01171

02513

00857

09926

00100

06082

09868

KB LAMINATES(01888) rose 10.63%, with a trading turnover 1.8 Billion HKD, and a year-to-date rose 158.8%. WEICHAI POWER(02338) rose 6.76%, with a trading turnover 1.1 Billion HKD, and a year-to-date rose 87.6%. AKESO(09926) fell 12.66%, with a trading turnover 3.1 Billion HKD, and a year-to-date rose 15.4%. MINIMAX-W(00100) fell 7.49%, with a trading turnover 1.5 Billion HKD, and a year-to-date rose 420.3%.

- The Hang Seng Index fell by 0.95%, with a year-to-date increase of 1.1%, while the Hang Seng Tech Index decreased by 1.98%, down 11.8% for the year.  
- Jian Tao Jici Ban (01888) rose by 10.63% with a trading volume of 1.76 billion HKD, marking a 158.8% year-to-date increase.  
- Weichai Power (02338) increased by 6.76% with a trading volume of 1.06 billion HKD, showing a 87.6% year-to-date rise, whereas Kangfang Biotech (09926) declined by 12.66%.

Top Gainers&Losers

KB LAMINATES

WEICHAI POWER

YANKUANG ENERGY

KNOWLEDGE ATLAS

PETROCHINA

AKESO

MINIMAX-W

BIREN TECH

XPENG-W

Top 5 HK Stock Gainers/Losers (>100B) (4.23)

06990

06181

01177

03317

06869

01772

SKB BIO(06990) rose 6.97%, with a trading turnover 458.1 Million HKD, and a year-to-date rose 32.3%. AKESO(09926) rose 6.89%, with a trading turnover 1.7 Billion HKD, and a year-to-date rose 30.4%. MINIMAX-W(00100) fell 10.88%, with a trading turnover 1.9 Billion HKD, and a year-to-date rose 413.6%. KNOWLEDGE ATLAS(02513) fell 8.54%, with a trading turnover 1.9 Billion HKD, and a year-to-date rose 646.1%.

SKB BIO

LAOPU GOLD

SBP GROUP

XUNCE

YOFC

GANFENGLITHIUM

Top 5 HK Stock Gainers/Losers (>100B) (4.15)

00883

002594

JP Morgan released a report listing the latest preferred stocks of Chinese companies, all of which have been given a "buy" rating. The list includes CNOOC, target price HKD 33; BYD, target price HKD 120; Northern Huachuang, target price RMB 610; MINIMAX-W, target price HKD 1,100; Zhizhu, target price HKD 950; Bank of China, target price HKD 5.5; INNOVENT BIO, target price HKD 111

AASTOCKS

CNOOC

JP Morgan lists the latest preferred stocks of Chinese companies (Table)

ADMA

Innovent Biologics announced preclinical results of IBI3055, a tri-specific T cell engager targeting autoimmune diseases, at the 2026 Immune Resetting Summit. IBI3055 targets CD19, BCMA, and CD3, designed to balance immune cell depletion with safety. Preclinical studies show it effectively depletes B cells and plasma cells, demonstrating favorable tolerability. Innovent aims to address unmet medical needs in autoimmune diseases with innovative therapies. Founded in 2011, Innovent partners with over 30 global healthcare companies and has launched 18 products, with several in advanced clinical trials.

prnewswire

Adma Biologics

iShares Global Healthcare

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Inovio Pharma

VanEck Biotech ETF

Health Care Select Sector SPDR

iShares Biotechnology ETF

Direxion S&P Biotech Bear 3X

iShares US Pharma

First Trust NYSE Arca Biotech Index Fd

Abcellera Biologics

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

VG Health

20:00 ETImmune Resetting: B-Cell Mediated & Beyond Summit 2026 Oral Presentation: Innovent Biologics Announces Pre-Clinical Results of IBI3055, a Tri-specific T Cell Engager Targeting Autoimmune Diseases

159849

588130

516500

516820

517110

510660

589720

600276

159837

The 12th Annual China Healthcare Investment Conference (CHIC 2026) celebrated outstanding achievements in healthcare investment at its Awards Gala Dinner in Shanghai. The event recognized key players in the sector, awarding Insilico Medicine for IPO of the Year, and Kailera Therapeutics and Vor Bio for Private Financing of the Year. Hengrui Pharma-GSK and Innovent-Takeda shared the Deal of the Year award. The conference connects innovation and investment in China's healthcare, featuring leaders from venture capital, private equity, and the pharmaceutical industry.

China Merchants CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Guotai SSE STAR Brand Name Drug ETF

Hengrui Pharma

E Fund CSI Biotechnology Theme ETF

20:00 ETCHIC 2026 Honors Landmark Deals and Financings at Annual Awards Gala

159859

588250

CMB International released a research report, expecting INNOVENT BIO to achieve strong performance in the fiscal year 2025, with a net profit of RMB 834 million and total revenue of RMB 13 billion, a year-on-year increase of 38%. Product sales are expected to reach RMB 11.9 billion, a year-on-year increase of 45%. Based on INNOVENT BIO's innovation capabilities and global development potential, the rating is maintained at "Buy," with the target price slightly raised from HKD 110.62 to HKD 113.86

Tianhong CNI BIOMEDICINE ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Yinhua CSI Innovative Drugs Industry ETF

ICBCCS SSE STAR Biology and Medicine ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

Minsheng Royal CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

CITIC International slightly raised INNOVENT BIO's target price to 113.86 yuan, accelerating its transformation towards global biopharmaceuticals

UB#INBIORC2611D(53958.HK)